Table 2.
Demographics and Clinical Characteristics of Groups Based on MRI Results
| Patient Characteristics | All | No Delayed Enhancement | Midwall Stripe | Scar | ANOVA P Value |
|---|---|---|---|---|---|
| n=130 | n=45 | n=30 | n=55 | ||
| Age, y | 67±12 | 66±11 | 64±16 | 70±10 | 0.038 |
| Sex, male | 88 (68%) | 25 (58%) | 19 (63%) | 44 (80%) | 0.029 |
| NYHA class | 0.411 | ||||
| I | 1 (1%) | 1 (2%) | 0 (0%) | 0 (0%) | |
| II | 35 (27%) | 16 (36%) | 5 (17%) | 14 (25%) | |
| III | 89 (68%) | 27 (60%) | 24 (80%) | 38 (69%) | |
| IV | 5 (4%) | 1 (2%) | 1 (3%) | 3 (5%) | |
| ACE‐I/ARB use | 110 (85%) | 41 (91%) | 26 (87%) | 43 (78%) | 0.192 |
| Beta‐blocker use | 115 (88%) | 43 (96%) | 27 (90%) | 45 (82%) | 0.097 |
| QRS duration, ms | 154±20 | 161±17 | 152±22 | 150±20 | 0.011 |
| PR interval, ms | 181±34 | 181±30 | 179±45 | 181±31 | 0.976 |
| Conduction | <0.001 | ||||
| LBBB | 86 (66%) | 40 (89%) | 23 (77%) | 23 (42%) | |
| RBBB | 17 (13%) | 1 (2%) | 1 (3%) | 15 (27%) | |
| IVCD | 24 (18%) | 2 (4%) | 6 (20%) | 16 (29%) | |
| RV‐paced | 3 (2%) | 2 (4%) | 0 (0%) | 1 (2%) | |
| Optimized | 67 (52%) | 27 (60%) | 12 (40%) | 28 (51%) | 0.235 |
| Lateral/posterolateral LV lead | 123 (%) | 42 (93%) | 28 (93%) | 53 (96%) | 0.751 |
| Pre‐CRT LVESV, mL | 120±57 | 121±68 | 132±69 | 112±36 | 0.267 |
| Pre‐CRT LVEDV, mL | 164±63 | 165±76 | 174±76 | 158±40 | 0.553 |
| Pre‐CRT EF, % | 29±7 | 28±8 | 26±8 | 31±6 | 0.004 |
ACE‐I indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; DE, delayed enhancement; EF, ejection fraction; IVCD, intraventricular conduction delay; LBBB, left bundle branch block; LV, left ventricular; LVEDV, left ventricular end‐diastolic volume; LVESV, left ventricular end‐systolic volume; NYHA, New York Heart Association; RV, right ventricular.